Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis Clinical Trial

Official title:
A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis

Status Completed

Clinical Trial Summary

To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in subjects with moderate to severe psoriasis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00936065
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 4
Start date	July 2009
Completion date	April 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00678470` - Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis	N/A
Terminated	`NCT01156532` - Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy	N/A
Completed	`NCT00256139` - CLEAR Study: Clinical Experience Acquired With Raptiva Study	Phase 3
Completed	`NCT00442650` - Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis	Phase 3
Completed	`NCT05344248` - Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing	Phase 1/Phase 2
Completed	`NCT03051217` - A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis	Phase 2/Phase 3